NOVEL SYNTHESIZED KPSAT PEPTIDES FOR CHRONIC LUNG DISEASE TREATMENT (RFT-704)
Invention Summary
Kisspeptins are peptide hormones that regulate pubertal development and sex hormone signaling. They interact with the KISS1R receptor, playing roles in various tissues beyond the neural and sex organs. The invention involves KISS1R agonists derived from kisspeptin-13 (KP-13), termed KP-13 satellites (KPSATs). These peptides are designed to improve therapeutic outcomes in lung diseases, particularly by exerting antiproliferative effects without cytotoxicity on airway smooth muscle (ASM) cells. KPSATs show enhanced efficacy in regulating extracellular matrix (ECM) productions and reducing lung tissue remodeling in conditions like asthma.
Benefits
- Non-cytotoxic-KPSATs do not harm lung cells, ensuring safety in therapeutic use.
- Antiproliferative-effectively reduce unwanted cell proliferation in lung tissues.
- Improved ECM Regulation-help maintain proper lung structure and function by modulating ECM components.
Applications
- Asthma -treats airway remodeling aspect b preventing abnormal tissue growth
- Chronic Obstructive Pulmonary Disease (COPD)-may slow progression and improve lung function
- Lymphangioleiomyomatosis (LAM) and Pulmonary Fibrosis-potential use in managing and reducing fibrotic tissue development in lungs.
Patent
This technology has a U.S. Patent Pending and is available for licensing/partnering opportunities.
Contact
NDSU Research Foundation
info(at)ndsurf(dot)org
(701) 231-8173
NDSURF Tech Key
RFT, 704, RFT704
Inquire about this technology >